FDA accepted Insmed’s sNDA for ARIKAYCE in MAC lung disease as part of combination therapy, granting Priority Review.
PDUFA target action date is set for Jan. 28, 2027.
The filing seeks full approval, supported by Phase 3b ENCORE results showing improved respiratory symptoms and higher culture conversion versus multidrug therapy alone.
INSM•
